Table A1.
Validation of Final Multivariable Model for Acute GVHD in Acute Leukemia
| Variable | Grade 2-4 Acute GVHD
|
Grade 3-4 Acute GVHD
|
||||
|---|---|---|---|---|---|---|
| RR | 95% CI | P | RR | 95% CI | P | |
| For recipients age 18-39 years | ||||||
| Bone marrow graft | 1.0 | 1.0 | ||||
| Peripheral blood stem-cell graft | 1.45 | 1.07 to 1.96 | .0161 | 1.98 | 1.23 to 3.19 | .0052 |
| For recipients age 40+ years | ||||||
| Bone marrow graft | 1.0 | 1.0 | ||||
| Peripheral blood stem-cell graft | 1.15 | 0.82 to 1.62 | .4059 | 1.68 | 1.02 to 2.74 | .0406 |
| Age for recipients of bone marrow transplants, years | ||||||
| 18-39 | 1.0 | 1.0 | ||||
| 40+ | 1.30 | 0.95 to 1.79 | .1067 | 1.58 | 0.95 to 2.64 | .0785 |
| Age for recipients of peripheral-blood stem-cell transplants, years | ||||||
| 18-39 | 1.0 | 1.0 | ||||
| 40+ | 1.04 | 0.75 to 1.44 | .8369 | 1.34 | 0.84 to 2.14 | .2182 |
| Race | ||||||
| Asian/Hispanic | 1.0 | 1.0 | ||||
| White/Black | 1.83 | 1.29 to 2.59 | .0007 | 1.04 | 0.65 to 1.66 | .8582 |
| Karnofsky performance score at transplant | ||||||
| 90-100 | 1.0 | 1.0 | ||||
| 0-80 | 1.17 | 0.92 to 1.49 | .2073 | 1.40 | 0.98 to 2.01 | .0647 |
| Conditioning regimen | ||||||
| BuCy ± other | 1.0 | 1.0 | ||||
| CyTBI ± other | 1.38 | 1.10 to 1.73 | .0054 | 1.12 | 0.80 to 1.57 | .5182 |
| Recipient-donor cytomegalovirus status | ||||||
| ≥ 1 positive | 1.0 | 1.0 | ||||
| Both negative | 1.05 | 0.82 to 1.35 | .6906 | 1.19 | 0.82 to 1.73 | .3494 |
Abbreviations: GVHD, graft-versus-host disease; RR, relative risk; BuCy ± other, busulfan and cyclophosphamide with or without additional agents; CyTBI ± other, cyclophosphamide and total body irradiation with or without additional agents; CMV, cytomegalovirus.